Weak Euro hits Fresenius profit estimates:
This article was originally published in Clinica
Executive Summary
Dialysis company Fresenius Medical Care (FMC) expects to have currency adjusted sales growth of over 10% this financial year, with a 25% increase in net income. The German company originally expected net income growth of up to 30%, but revised its estimates because of the weak euro in the first half, Bad Homburg-based FMC said. It has filed with the US Securities and Exchange Commission and the Frankfurt stock exchange for a global offering. It plans to use the proceeds to fund acquisitions (see Clinica No 914, p 9).